AET تصريحات هيئة الأوراق المالية والبورصات - Aetna, Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

LEI	549300QKBENKLBXQ8968
CIK	1122304

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aetna, Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

December 10, 2018	15-12B	AET / Aetna, Inc. FORM 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-16095 AETNA INC. (Exact name of registrant as specified in its charter)
December 4, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2018 (November 30, 2018 ) Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IR
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS S-8 POS 1 dp98211s8pos-52120.htm FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No. 333-219668 Registration No. 333-212841 Registration No. 333-197707 Registration No. 333-190272 Registration No. 333-188814 Registration No. 333-188792 Registration No. 333-176011 Registration No. 333-176009 Registration No. 333-168498 Registration No. 333-168497
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS S-8 POS 1 dp98210s8pos-52122.htm FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No. 333-219668 Registration No. 333-212841 Registration No. 333-197707 Registration No. 333-190272 Registration No. 333-188814 Registration No. 333-188792 Registration No. 333-176011 Registration No. 333-176009 Registration No. 333-168498 Registration No. 333-168497
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS S-8 POS 1 dp98202s8pos-136177.htm FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No. 333-219668 Registration No. 333-212841 Registration No. 333-197707 Registration No. 333-190272 Registration No. 333-188814 Registration No. 333-188792 Registration No. 333-176011 Registration No. 333-176009 Registration No. 333-168498 Registration No. 333-168497
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS S-8 POS 1 dp98197s8pos-188792.htm FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No. 333-219668 Registration No. 333-212841 Registration No. 333-197707 Registration No. 333-190272 Registration No. 333-188814 Registration No. 333-188792 Registration No. 333-176011 Registration No. 333-176009 Registration No. 333-168498 Registration No. 333-168497
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	S-8 POS	AET / Aetna, Inc. FORM S-8 POS S-8 POS 1 dp98192s8pos-219668.htm FORM S-8 POS As filed with the Securities and Exchange Commission on November 29, 2018 Registration No. 333-219668 Registration No. 333-212841 Registration No. 333-197707 Registration No. 333-190272 Registration No. 333-188814 Registration No. 333-188792 Registration No. 333-176011 Registration No. 333-176009 Registration No. 333-168498 Registration No. 333-168497
November 29, 2018	POSASR	AET / Aetna, Inc. FORM POSASR As filed with the Securities and Exchange Commission on November 29, 2018 Registration No.
November 29, 2018	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 10, 2018, pursuant to the provisions of Rule 12d2-2 (a).
November 28, 2018	EX-3.2	Amended and Restated Bylaws of Aetna Inc. EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS OF AETNA INC. (A Pennsylvania Business Corporation) ARTICLE I SHAREHOLDERS 1.1 Meetings. 1.1.1 Place. Meetings of the shareholders shall be held at such place within or without the Commonwealth as may be designated by the Board of Directors. 1.1.2 Annual Meeting. An annual meeting of the shareholders for the election of directors and for other business shall
November 28, 2018	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer incorpora
November 28, 2018	EX-3.1	Second Amended and Restated Articles of Incorporation of Aetna Inc. EXHIBIT 3.1 SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION OF AETNA INC. (A Pennsylvania Corporation) 1.Name. The name of the corporation is Aetna Inc. (the “Corporation”). 2.Registered Office. The address of the Corporation’s registered office in the Commonwealth of Pennsylvania is the Corporation’s principal office at 1425 Union Meeting Road, Blue Bell, PA 19422 (which is located in Montg
November 26, 2018	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-01011 05-0494040 (
November 26, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer incorpora
November 20, 2018	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 19, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-01011 05-0494040 (Comm
November 6, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-6 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
November 6, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-6 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
October 30, 2018	EX-99.1	AETNA REPORTS THIRD-QUARTER 2018 RESULTS 151 Farmington Avenue Hartford, Conn. 06156 Media Contact: Ethan Slavin 860-273-6095 [email protected] Investor Contact: Joe Krocheski 860-273-0896 [email protected] News Release AETNA REPORTS THIRD-QUARTER 2018 RESULTS HARTFORD, Conn., October 30, 2018 - Aetna (NYSE: AET) announced third-quarter 2018 net income(1) of $1.0 billion, or $3.03 per share. Adjusted earnings(2) for third-quarter 2018
October 30, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer incorporat
October 30, 2018	EX-15.1	Letter from KPMG LLP acknowledging awareness of the use of a report dated October 30, 2018 related to their reviews of interim financial information. Exhibit 15.1 Aetna Inc. Hartford, Connecticut Re: Registration Statement Nos. 333-221818, 52120, 52122, 52124, 73052, 87722, 87726, 124619, 124620, 136176, 136177, 168497, 168498, 176009, 176011, 188792, 188814, 190272, 197707, 212841 and 219668 With respect to the subject registration statements, we acknowledge our awareness of the use therein of our report dated October 30, 2018 related to our r
October 30, 2018	10-Q	AET / Aetna, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-16095 Aetna I
October 30, 2018	EX-12.1	Computation of ratio of earnings to fixed charges. Exhibit 12.1 Computation of Ratios The computation of the ratio of earnings to fixed charges for the nine months ended September 30, 2018 and the years ended December 31, 2017, 2016, 2015, 2014 and 2013 are as follows: Nine Months Ended September 30, 2018 Years Ended December 31, (Millions) 2017 2016 2015 2014 2013 Income from continuing operations before income taxes $ 4,498 $ 2,991 $ 3,991 $ 4,2
October 26, 2018	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) 425 1 d646052d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 001-01011 05-0494040 (State or Other Jurisdiction
October 26, 2018	EX-10.1	364-Day Bridge Term Loan Agreement, dated October 26, 2018, by and among CVS Health Corporation, Barclays Bank PLC, as administrative agent, and the lenders party thereto. EX-10.1 Exhibit 10.1 EXECUTION VERSION 364-DAY BRIDGE TERM LOAN AGREEMENT dated as of October 26, 2018 by and among CVS HEALTH CORPORATION the Lenders Party Hereto GOLDMAN SACHS BANK USA and BANK OF AMERICA, N.A., as Co-Syndication Agents and BARCLAYS BANK PLC, as Administrative Agent BARCLAYS BANK PLC, GOLDMAN SACHS BANK USA and MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED, as Joint Lead Ar
October 22, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-6 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
October 11, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2018 (October 10, 2018) Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS
October 10, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-6 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
October 10, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-6 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
October 10, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer incorporat
September 27, 2018	425	CVS / CVS Health Corporation REGULATION 425 (Prospectus) Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-6 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
September 27, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2018 (September 26, 2018) Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (
August 14, 2018	CORRESP	AET / Aetna, Inc. CORRESP VIA EDGAR CORRESPONDENCE August 14, 2018 United States Securities and Exchange Commission Division of Corporation Finance Washington, D.
August 8, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-6 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
August 2, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer incorporatio
August 2, 2018	EX-99.1	AETNA REPORTS SECOND-QUARTER 2018 RESULTS 151 Farmington Avenue Hartford, Conn. 06156 Media Contact: T.J. Crawford 212-457-0583 [email protected] Investor Contact: Joe Krocheski 860-273-0896 [email protected] News Release AETNA REPORTS SECOND-QUARTER 2018 RESULTS HARTFORD, Conn., August 2, 2018 - Aetna (NYSE: AET) announced second-quarter 2018 net income(1) of approximately $1.2 billion, or $3.67 per share. Adjusted earnings(2) for
August 2, 2018	10-Q	AET / Aetna, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-16095 Aetna Inc. (
August 2, 2018	EX-15.1	Letter from KPMG LLP acknowledging awareness of the use of a report dated August 2, 2018 related to their reviews of interim financial information. EX-15.1 3 exhibit151.htm EXHIBIT 15.1 Exhibit 15.1 Aetna Inc. Hartford, Connecticut Re: Registration Statement Nos. 333-221818, 52120, 52122, 52124, 73052, 87722, 87726, 124619, 124620, 136176, 136177, 168497, 168498, 176009, 176011, 188792, 188814, 190272, 197707, 212841 and 219668 With respect to the subject registration statements, we acknowledge our awareness of the use therein of our report d
August 2, 2018	EX-12.1	Computation of ratio of earnings to fixed charges. Exhibit 12.1 Computation of Ratios The computation of the ratio of earnings to fixed charges for the six months ended June 30, 2018 and the years ended December 31, 2017, 2016, 2015, 2014 and 2013 are as follows: Six Months Ended June 30, 2018 Years Ended December 31, (Millions) 2017 2016 2015 2014 2013 Income from continuing operations before income taxes $ 3,131 $ 2,991 $ 3,991 $ 4,234 $ 3,497 $
July 26, 2018	CORRESP	AET / Aetna, Inc. CORRESP VIA EDGAR CORRESPONDENCE July 26, 2018 United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance Washington, D.
July 25, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 1 d582100d425.htm 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-6 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc. Commission File No.: 001-16095 Date: July 25, 2018 The following financial information was included in the Current Report on Form 8-K filed by CVS Health Corporation with the Sec
June 28, 2018	11-K	AET / Aetna, Inc. FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One): [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-16095 A. Full title of the pla
June 26, 2018	CORRESP	AET / Aetna, Inc. CORRESP CORRESP 1 filename1.htm VIA EDGAR CORRESPONDENCE June 26, 2018 United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: Aetna Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Filed February 23, 2018 File No. 001-16095 Ladies and Gentlemen: We are in receipt of the letter from the Securities and Exchange Commission to Aetna Inc. (“Aetna”)
June 18, 2018	CORRESP	AET / Aetna, Inc. CORRESP VIA EDGAR CORRESPONDENCE June 18, 2018 United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance Washington, D.
June 6, 2018	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) 425 1 d598957d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-01011
June 6, 2018	EX-99.1	CVS Health Announces Management Team for Combined Company Following Close of Aetna Acquisition Transaction Executives of both companies appointed to drive forward future vision Transaction expected to close in second half of 2018, subject to required EX-99.1 Exhibit 99.1 CVS Health Announces Management Team for Combined Company Following Close of Aetna Acquisition Transaction Executives of both companies appointed to drive forward future vision Transaction expected to close in second half of 2018, subject to required regulatory approvals Woonsocket, RI (June 6, 2018) – CVS Health (NYSE: CVS) today announced the management team that following t
May 22, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2018 (May 18, 2018) Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer
May 14, 2018	CORRESP	AET / Aetna, Inc. CORRESP VIA EDGAR CORRESPONDENCE May 14, 2018 United States Securities and Exchange Commission Division of Corporation Finance Washington, D.
May 2, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-6 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
May 1, 2018	EX-99.1	AETNA REPORTS FIRST-QUARTER 2018 RESULTS 151 Farmington Avenue Hartford, Conn. 06156 Media Contact: Ethan Slavin 860-273-6095 [email protected] Investor Contact: Joe Krocheski 860-273-0896 [email protected] News Release AETNA REPORTS FIRST-QUARTER 2018 RESULTS HARTFORD, Conn., May 1, 2018 - Aetna (NYSE: AET) announced first-quarter 2018 net income(1) of $1.2 billion, or $3.67 per share. Adjusted earnings(2) for first-quarter 2018 were
May 1, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer incorporation)
May 1, 2018	EX-10.3	Letter agreement dated September 25, 2017, between Aetna Life Insurance Company and Richard M. Jelinek.* Exhibit 10.3 151 Farmington Avenue Hartford, CT 06156 [Aetna Logo] Thomas W. Weidenkopf Executive Vice President Human Resources Office: 212.457.0752 To: Rick Jelinek From: Tom Weidenkopf Date: September 25, 2017 Subject: Amendment to Employment Letter The purpose of this memorandum is to outline the agreement we have reached regarding the definition of "Good Reason" set forth in the employment le
May 1, 2018	EX-10.1	Letter agreement dated October 14, 2015, between Aetna Life Insurance Company and Richard M. Jelinek.* Exhibit 10.1 [Aetna Logo] Mark Bertolini Chairman and Chief Executive Officer Aetna 151 Farmington Avenue Hartford, CT 06156 860-273-1188 October 14, 2015 Rick Jelinek Dear Rick: We are pleased to offer you the position of Executive Vice President, Humana Integration. We look forward to having you start work on or before November 2, 2015. Your principal work location will be your home in Minnesota
May 1, 2018	EX-10.2	Letter agreement dated March 7, 2017, between Aetna Life Insurance Company and Richard M. Jelinek.* EX-10.2 3 exhibit102.htm EXHIBIT 10.2 Exhibit 10.2 151 Farmington Ave., REAG Hartford, CT 06156 [Aetna Logo] Brennan Hinkle VP, Compensation Aetna HR Office: 860-273-6978 Fax: 860-902-7702 To: Rick Jelinek Date: March 7, 2017 From: Brennan Hinkle Subject: Amendment to Employment Letter The purpose of this memorandum is to outline the agreement we have reached regarding the definition of “Good Reas
May 1, 2018	EX-15.1	Letter from KPMG LLP acknowledging awareness of the use of a report dated May 1, 2018 related to their review of interim financial information. EX-15.1 6 exhibit151.htm EXHIBIT 15.1 Exhibit 15.1 Aetna Inc. Hartford, Connecticut Re: Registration Statement Nos. 333-221818, 52120, 52122, 52124, 73052, 87722, 87726, 124619, 124620, 136176, 136177, 168497, 168498, 176009, 176011, 188792, 188814, 190272, 197707, 212841 and 219668 With respect to the subject registration statements, we acknowledge our awareness of the use therein of our report d
May 1, 2018	10-Q	AET / Aetna, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 form10-q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi
May 1, 2018	EX-12.1	Computation of ratio of earnings to fixed charges. Exhibit 12.1 Computation of Ratios The computation of the ratio of earnings to fixed charges for the three months ended March 31, 2018 and the years ended December 31, 2017, 2016, 2015, 2014 and 2013 are as follows: Three Months Ended March 31, 2018 Years Ended December 31, (Millions) 2017 2016 2015 2014 2013 Income from continuing operations before income taxes $ 1,465 $ 2,991 $ 3,991 $ 4,234 $ 3
April 17, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer incorporatio
April 17, 2018	EX-99.1	AETNA TO RELEASE FIRST-QUARTER 2018 RESULTS; ANNOUNCES BUSINESS SEGMENT REALIGNMENT EX-99.1 2 exhibit991.htm EXHIBIT 99.1 151 Farmington Avenue Hartford, Conn. 06156 Media Contact: T.J. Crawford 212-457-0583 [email protected] Investor Contact: Joe Krocheski 860-273-0896 [email protected] News Release AETNA TO RELEASE FIRST-QUARTER 2018 RESULTS; ANNOUNCES BUSINESS SEGMENT REALIGNMENT HARTFORD, Conn., April 17, 2018 - Aetna (NYSE: AET) today announced that first-quarter 2018
April 6, 2018	DEFA14A	AET / Aetna, Inc. DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 6, 2018	DEFA14A	AET / Aetna, Inc. DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 6, 2018	DEF 14A	I_L6N0RA++3 MF(B5OE-6)9:;R!5&\!,2M- A-/ "FW0#1EA+PT; MA6#EJC OV;1[(=IZ_%8: TT>90MFS=L]WTV6&&CP-/75;-F68YSS6& J1Z7Q M]?@M&&N4]S2MF&4>AP&_H@F&J9\\C9;,-13/':^7ZK$;-HQ<)T6& DZ-1I@_ MDL-!BFT:S1^"RS :F:W4=UEF!BF!G4(&Z%9H-4S TI6[,!1K?3C;JLLT&5 MFKIJA& S6 begin 644 aetcourtesy-pdf.pdf M)5!$1BTQ+C,-)>+CS],-"C$@,"!O8FH-/#PO365T861A=&$@,B P(%(O3W5T M<'5T26YT96YT7!E+T]U='!U=$EN=&5N=#X^72]0 M86=E3&%B96QS(#8@,"!2+U!A9V5S(#,@,"!2+U1Y<&4O0V%T86QO9R]6:65W M97)0FMC.60B/SX/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O7!E+U)E M&UL;G,Z&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @ M(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT M&UL M;G,Z<&1F>#TB:'
April 6, 2018	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) aetna3346211-def14a1.htm - Generated by SEC Publisher for SEC Filing Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐
March 15, 2018	EX-99.1	AETNA SHAREHOLDERS OVERWHELMINGLY APPROVE PROPOSED ACQUISITION BY CVS HEALTH Exhibit 99.1 Media Contact: T.J. Crawford 212-457-0583 [email protected] Investor Contact: Joe Krocheski 860-273-0896 [email protected] News Release AETNA SHAREHOLDERS OVERWHELMINGLY APPROVE PROPOSED ACQUISITION BY CVS HEALTH HARTFORD, Conn., Mar. 13, 2018 - At today’s special meeting of Aetna (NYSE: AET) shareholders, approximately 97 percent of the votes cast, and over 77 percent of the 32
March 15, 2018	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2018 (March 13, 2018) Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Empl
March 13, 2018	EX-99.1	CVS Health Stockholders Approve Aetna Acquisition Transaction expected to close in second half of 2018, subject to regulatory approvals Combined company will focus on remaking the consumer health care experience, lowering health care costs EX-99.1 Exhibit 99.1 CVS Health Stockholders Approve Aetna Acquisition Transaction expected to close in second half of 2018, subject to regulatory approvals Combined company will focus on remaking the consumer health care experience, lowering health care costs WOONSOCKET, R.I., March 13, 2018 – In a special meeting held today, CVS Health Corporation (NYSE:CVS) stockholders voted to approve the sha
March 13, 2018	425	CVS / CVS Health Corporation 8-K (Prospectus) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-01011 05-0494040 (Commissi
March 12, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) CVS Health – Aetna integration planning update 2 © 201 8 A etna Inc. Key accomplishments x Kicked off integration p
March 12, 2018	EX-4.7	Form of the 2028 Note EX-4.7 Exhibit 4.7 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH
March 12, 2018	EX-4.3	Form of the 2020 Note EX-4.3 Exhibit 4.3 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH
March 12, 2018	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) 001-01011 Delaware 05-0494040 (Commission File Number) (State or Other Jurisdictio
March 12, 2018	EX-1.1	Underwriting Agreement dated March 6, 2018 among CVS Health Corporation and Barclays Capital Inc., Goldman Sachs & Co. LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC as representatives of the Underwriters named in Schedule I thereto EX-1.1 Exhibit 1.1 CVS HEALTH CORPORATION $1,000,000,000 Floating Rate Notes due 2020 $1,000,000,000 Floating Rate Notes due 2021 $2,000,000,000 3.125% Senior Notes due 2020 $3,000,000,000 3.350% Senior Notes due 2021 $6,000,000,000 3.700% Senior Notes due 2023 $5,000,000,000 4.100% Senior Notes due 2025 $9,000,000,000 4.300% Senior Notes due 2028 $5,000,000,000 4.780% Senior Notes due 2038 $8,000
March 12, 2018	EX-4.6	Form of the 2025 Note EX-4.6 Exhibit 4.6 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH
March 12, 2018	EX-4.2	Form of the 2021 Floating Rate Note EX-4.2 Exhibit 4.2 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH
March 12, 2018	EX-4.1	Form of the 2020 Floating Rate Note EX-4.1 Exhibit 4.1 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH
March 12, 2018	EX-4.9	Form of the 2048 Note EX-4.9 Exhibit 4.9 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH
March 12, 2018	EX-4.5	Form of the 2023 Note EX-4.5 Exhibit 4.5 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH
March 12, 2018	EX-4.8	Form of the 2038 Note EX-4.8 Exhibit 4.8 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH
March 12, 2018	EX-4.4	Form of the 2021 Note EX-4.4 Exhibit 4.4 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH
March 9, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication was made available on Aetna’s internal website: A conversation with Karen Lynch and Lar
March 8, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
March 8, 2018	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-01011 05-0494040 (Comm
March 6, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication was made available by Aetna on Twitter: Thank you Larry Merlo, President and CEO of @CV
March 6, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
March 6, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following are excerpts of a transcript of a video made available on Aetna’s internal website: Aetna Commercial
March 6, 2018	EX-99.1	1 EX-99.1 Exhibit 99.1 The following sets forth the Business discussion and Regulatory Environment discussion of Aetna Inc. (“Aetna”) and its subsidiaries described in Part I, Item 1 and Part II, Item 7 in Aetna’s Annual Report on Form 10-K for the year ended December 31, 2017 and filed with the Securities and Exchange Commission (“SEC”) on February 23, 2018. In this Exhibit 99.1, “we”, “our”, “us”,
March 6, 2018	EX-99.2	1 EX-99.2 Exhibit 99.2 The following sets forth the Risk Factors discussion of Aetna Inc. (“Aetna”) and its subsidiaries described in Part I, Item 1A in Aetna’s Annual Report on Form 10-K for the year ended December 31, 2017 and filed with the Securities and Exchange Commission (“SEC”) on February 23, 2018. In this Exhibit 99.2, “we”, “our”, “us”, and “the Company” refer to Aetna and its subsidiarie
March 6, 2018	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) 425 1 d532752d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-0
March 2, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
March 1, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following is an excerpt of a transcript from an Aetna town hall: Aetna CONSUMER HEALTH PRODUCTS TOWN HALL Dave
March 1, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication was made available by Aetna: Aetna President Karen Lynch on the future of health care S
March 1, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following is a transcript of a video made available by Aetna: Merlo 1. I can’t think of any greater opportunity
March 1, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) 425 1 dp87464425-90.htm FORM 425 Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication was made available on Aetna’s internal website: Game o
February 28, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following is an excerpt of a transcript from an Aetna town hall: Aetna HR Town Hall Tom Weidenkopf […] So in te
February 28, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 28, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 28, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication was made available by Aetna: Thomas M. Moriarty Executive Vice President, Chief Policy
February 28, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication was made available on Aetna?s internal website: Congressional hearing on proposed Aetna
February 28, 2018	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-01011 05-0494040 (
February 28, 2018	EX-99.1	27 (Millions) 2017 2016 2015 Proceeds on sales $ 5,753 $ 6,725 $ 4,987 Gross realized capital gains 114 155 83 Gross realized capital losses 47 61 76 EX-99.1 Exhibit 99.1 Consolidated Balance Sheets At December 31, (Millions) 2017 2016 Assets: Current assets: Cash and cash equivalents $ 4,076 $ 17,996 Investments 2,280 3,046 Premiums receivable, net 2,240 2,356 Other receivables, net 2,831 2,224 Reinsurance recoverables 1,050 292 Accrued investment income 193 232 Income taxes receivable 365 44 Other current assets 2,488 2,259 Total current asse
February 28, 2018	8-K	Other Events 8-K 1 dp873238k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commi
February 28, 2018	425	AET / Aetna, Inc. FORM 8-K (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer incorpora
February 28, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2018 (February 27, 2018) Aetna Inc. (Exact Name of Registrant as Specified in its Charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of incorporation)
February 28, 2018	425	AET / Aetna, Inc. FORM 8-K (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2018 (February 27, 2018) Aetna Inc. (Exact Name of Registrant as Specified in its Charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of incorporation)
February 28, 2018	EX-99.2	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EX-99.2 5 d443196dex992.htm EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The unaudited pro forma condensed combined statement of income for the year ended December 31, 2017 combines the historical consolidated statements of income of CVS Health Corporation (“CVS Health”) and Aetna Inc. (“Aetna”), giving effect to the merger (as defined below) as if it had occurr
February 26, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 26, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following is a transcript of a video made available by Aetna: CBS This Morning Interview with Aetna Chairman an
February 26, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication was made available by Aetna: Changing a ?backwards? health care system The way the curr
February 26, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication was made available on Aetna?s internal website: Mark Bertolini talks to CBS about chang
February 26, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Fixed Income Presentation February 2018 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 24, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 23, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) 425 1 dp87174425-82.htm FORM 425 Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following statement will be made by Aetna: Statement of Thomas J. Sabatino, Jr
February 23, 2018	EX-99.1	Risk Factors of CVS Health Corporation EX-99.1 13 exhibit991.htm EXHIBIT 99.1 Exhibit 99.1 The following sets forth the risk factors of CVS Health Corporation (“CVS Health”) and its subsidiaries described in Part I, Item 1A of CVS Health's Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (the "SEC") on February 14, 2018, which is incorporated by reference in Aetna Inc.'s
February 23, 2018	EX-21.1	Subsidiaries of Aetna Inc. Exhibit 21.1 Subsidiaries of Aetna Inc. Listed below are subsidiaries of Aetna Inc. at December 31, 2017 with their jurisdictions of organization shown in parentheses. Subsidiaries excluded from the list below would not, in the aggregate, constitute a “significant subsidiary” of Aetna Inc., as that term is defined in Rule 1-02(w) of Regulation S-X. • Aetna Health Holdings, LLC (Delaware) ◦ Aetna H
February 23, 2018	EX-12.1	Computation of ratio of earnings to fixed charges. Exhibit 12.1 Statement re: Computation of Ratios The computation of the ratio of earnings to fixed charges for the years ended December 31, 2013 through 2017 are as follows: Years Ended December 31, (Millions) 2017 2016 2015 2014 2013 Income from continuing operations before income taxes $ 2,991 $ 3,991 $ 4,234 $ 3,497 $ 2,937 Add back fixed charges 498 663 426 396 396 Income as adjusted ("earning
February 23, 2018	EX-24.1	Power of Attorney. EX-24.1 8 exhibit241.htm POWER OF ATTORNEY Exhibit 24.1 Power of Attorney We, the undersigned Directors of Aetna Inc. (the “Company”), hereby severally constitute and appoint Shawn M. Guertin, Heather Dixon and William C. Baskin III, and each of them individually, our true and lawful attorneys-in-fact, with full power to them and each of them to sign for us, and in our names and in the capacities
February 23, 2018	EX-10.41	Letter agreement dated December 22, 2017, between Aetna Inc. and Thomas J. Sabatino, Jr. ** Exhibit 10.41 [Aetna Logo] Aetna Inc. 151 Farmington Avenue Hartford, CT 06156 Thomas W. Weidenkopf Executive Vice President and Chief Human Resources Officer Phone: 212-457-0752 December 22, 2017 Thomas J. Sabatino, Jr. Executive Vice President and General Counsel 100 Park Avenue, 12th Floor New York, NY 10017 Dear Tom, In connection with the transactions contemplated by the Agreement and Plan of
February 23, 2018	10-K	AET / Aetna, Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-16095 Aetna Inc. (Exact
February 23, 2018	EX-10.40	Letter agreement dated December 22, 2017, between Aetna Inc. and Richard M. Jelinek. ** EX-10.40 3 exhibit1040.htm EXHIBIT 10.40 Exhibit 10.40 [Aetna Logo] Aetna Inc. 151 Farmington Avenue Hartford, CT 06156 Thomas W. Weidenkopf Executive Vice President and Chief Human Resources Officer Phone: 212-457-0752 December 22, 2017 Richard M. Jelinek Executive Vice President, Enterprise Strategy 100 Park Avenue, 12th Floor New York, NY 10017 Dear Rick, In connection with the transactions con
February 23, 2018	EX-10.39	Letter agreement dated December 22, 2017, between Aetna Inc. and Gary W. Loveman. ** Exhibit 10.39 [Aetna Logo] Aetna Inc. 151 Farmington Avenue Hartford, CT 06156 Thomas W. Weidenkopf Executive Vice President and Chief Human Resources Officer Phone: 212-457-0752 December 22, 2017 Gary W. Loveman Executive Vice President, Consumer Health and Services 93 Worcester Street Wellesley, MA 02481 Dear Gary, In connection with the transactions contemplated by the Agreement and Plan of Mer
February 20, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2018 (February 13, 2018) Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commi
February 20, 2018	EX-10.1	Separation Agreement dated February 13, 2018, between Aetna Inc. and Gary W. Loveman, Ph. D.* Exhibit Exhibit 10.1 151 Farmington Avenue Hartford, CT 06156 [Aetna Logo] Thomas W. Weidenkopf Executive Vice President, Human Resources February 13, 2018 Gary W. Loveman Dear Gary, The purpose of this document is to confirm the agreement we have reached as a result of our discussions regarding your cessation of your employment with Aetna Inc., Aetna Life Insurance Company and/or one or more of A
February 16, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 16, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) 425 1 dp86937425-81.htm FORM 425 Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following is an excerpt of a communication that was made available on Aetna’s
February 15, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication will be distributed by Aetna: Special Meeting of Aetna Shareholders - CVS Transaction M
February 15, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication will be distributed by Aetna: Special Meeting of Aetna Shareholders - CVS Transaction M
February 14, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication will be distributed by Aetna: 151 Farmington Avenue Hartford, CT 06156 Jin D. Lee Execu
February 13, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The following communication has been distributed by Aetna: ?2018 Aetna Inc. 95.35.110.1 (1/18) Dear Name , You may
February 12, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 12, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 12, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 12, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The below will be sent to brokers who hold Aetna shares on behalf of beneficial owners: No Offer or Solicitation Th
February 12, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No. for Registration Statement on Form S-4 filed by CVS Heath Corporation: 333-222412) The below will be sent to participants in Aetna?s 401(k) Plan: No Offer or Solicitation This communication is for i
February 9, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 9, 2018	DEFM14A	AET / Aetna, Inc. DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitte
February 9, 2018	8-K	Other Events 8-K 1 form8-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commissi
February 9, 2018	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-01011 05-0494040 (C
February 8, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Fourth Quarter 2017 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer February 8, 2018 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 8, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following are excerpts from a communication made available on Aetna’s internal website: Aetna Karen Lynch Speech [ 00:00:06 ] karen lynch Good afternoon. Hello. Good morning to those o
February 8, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 8, 2018	SC 13G/A	AET / Aetna, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 aetnainc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: Aetna Inc Title of Class of Securities: Common Stock CUSIP Number: 00817Y108 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate box to designate the rule pursuant to which this Sched
February 6, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following is an excerpt of a transcript from an Aetna town hall: AETNA Aetna International Town Hall [ 00:00:06 ] RICHARD DI BENEDETTO Before I go to that, I know, I know a lot of you,
February 2, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
February 1, 2018	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2018 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-01011 05-0494040 (C
February 1, 2018	8-K	AET / Aetna, Inc. FORM 8-K (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer i
January 31, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following communication was made available on Aetna?s internal website: Amazon, others join the effort to transform health care Posted by Dave Werry, Vice President, Consumer Health Pr
January 30, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 30, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 30, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) 425 1 dp85915425-68.htm FORM 425 Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) Aetna made the following statement: There is an unmet consumer need in health care. Individuals and families want a simple, affordable and high-quality exp
January 30, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following are excerpts of a communication made available on Aetna?s internal website: As Mark announced today, Rick Jelinek will lead the CVS integration efforts to continue our strate
January 30, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer i
January 30, 2018	EX-99.1	AETNA REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS Exhibit 151 Farmington Avenue Hartford, Conn. 06156 Media Contact: T.J. Crawford 212-457-0583 [email protected] Investor Contact: Joe Krocheski 860-273-0896 [email protected] News Release AETNA REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS HARTFORD, Conn., January 30, 2018 - Aetna (NYSE: AET) announced fourth-quarter 2017 net income (1) of $244 million , or $0.74 per share. Adjusted earn
January 29, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following communication was made available on Aetna?s internal website: Message from Mark Bertolini: Rick Jelinek to lead Aetna integration Colleagues, I am pleased to announce that Ri
January 26, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) Q&A on proposed transaction with CVS Health Updated Jan. 26, 2018 Contents Announcement 1 Employee- and benefits-related 1 Agreement, approvals and closing 5 Integration 5 Customers and ot
January 25, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2018 Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of (Commission (IRS Employer i
January 24, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 22, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 19, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) CVS Health + Aetna: Revolutionizing the Consumer Health Care Experience Important Information for Investors and Shareholders 2 No Offer or Solicitation This communication is for informatio
January 18, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 CVS Health A New Health Care Innovation Model January 18, 2018 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 16, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 11, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 10, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 1 d516157d425.htm 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc. Commission File No.: 001-16095 Date: January 10, 2018 January 10, 2018 The following articles written by third parties were made available to employees of CVS Health Corporation
January 9, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 8, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 8, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 4, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 4, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 2018 Guidance Conference Call Dave Denton Executive Vice President & Chief Financial Officer January 4, 2018 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 4, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 3, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 3, 2018	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
January 3, 2018	425	AET / Aetna, Inc. FORM 425 (Prospectus) 425 1 dp84836425-62.htm FORM 425 Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) Message from Mark Bertolini All, I hope that each of you took time to relax and start the New Year with friends and family. While 2017 was certainly an his
December 28, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 26, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 22, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2017 (December 19, 2017) Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of incorporation)
December 22, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 21, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 21, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following provider talking points may be distributed by Aetna: ? The goal is to continue to complement and strengthen the valuable relationships consumers have with their physicians. T
December 21, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following communication was distributed by Aetna: A Message to Providers With the news of the proposed acquisition of Aetna by CVS Health, different stakeholders in the health care sys
December 20, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 20, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) 425 1 dp84238425-58.htm FORM 425 Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following are excerpts from a transcript of a video made available to Aetna employees: RICK JELINEK MESSAGE TO ALL MARKETS ASSOCIATES Hello. I’m happy
December 19, 2017	EX-10.1	Term Loan Agreement, dated as of December 15, 2017, by and among CVS Health Corporation, the lenders party thereto and Barclays Bank PLC, as administrative agent. EX-10.1 Exhibit 10.1 TERM LOAN AGREEMENT dated as of December 15, 2017 by and among CVS HEALTH CORPORATION the Lenders Party Hereto GOLDMAN SACHS BANK USA and BANK OF AMERICA, N.A., as Co-Syndication Agents and BARCLAYS BANK PLC, as Administrative Agent BARCLAYS BANK PLC, GOLDMAN SACHS BANK USA, MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED, JPMORGAN CHASE BANK, N.A. and WELLS FARGO BANK, N.A
December 19, 2017	425	CVS / CVS Health Corporation 8-K (Prospectus) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2017 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-01011 05-0494040 (Commi
December 19, 2017	EX-10.4	Amendment No. 1 to Second Amended and Restated Credit Agreement, dated as of December 15, 2017, among CVS Health, the lenders party thereto and The Bank of New York Mellon, as administrative agent. EX-10.4 Exhibit 10.4 AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT AMENDMENT NO. 1 (this ?Amendment?), dated as of December 15, 2017, is entered into among CVS Health Corporation, a Delaware corporation (the ?Borrower?), The Bank of New York Mellon, as Administrative Agent and the Lenders party hereto (the ?Consenting Lenders?). Except as otherwise provided herein, capitalized te
December 19, 2017	EX-10.3	Amendment No. 1 to Five Year Credit Agreement, dated as of December 15, 2017, among CVS Health, the lenders party thereto and The Bank of New York Mellon, as administrative agent. EX-10.3 Exhibit 10.3 AMENDMENT NO. 1 TO FIVE YEAR CREDIT AGREEMENT AMENDMENT NO. 1 (this ?Amendment?), dated as of December 15, 2017, is entered into among CVS Health Corporation, a Delaware corporation (the ?Borrower?), The Bank of New York Mellon, as Administrative Agent and the Lenders party hereto (the ?Consenting Lenders?). Except as otherwise provided herein, capitalized terms used herein wh
December 19, 2017	EX-10.2	Amendment No. 1 to 364-Day Credit Agreement, dated as of December 15, 2017, among CVS Health, the lenders party thereto and The Bank of New York Mellon, as administrative agent. EX-10.2 4 d508259dex102.htm EX-10.2 Exhibit 10.2 AMENDMENT NO. 1 TO 364-DAY CREDIT AGREEMENT AMENDMENT NO. 1 (this “Amendment”), dated as of December 15, 2017, is entered into among CVS Health Corporation, a Delaware corporation (the “Borrower”), The Bank of New York Mellon, as Administrative Agent and the Lenders party hereto (the “Consenting Lenders”). Except as otherwise provided herein, capita
December 19, 2017	EX-10.5	Amendment No. 1 to Credit Agreement, dated as of December 15, 2017, among CVS Health, the lenders party thereto and The Bank of New York Mellon, as administrative agent. EX-10.5 Exhibit 10.5 AMENDMENT NO. 1 TO CREDIT AGREEMENT AMENDMENT NO. 1 (this ?Amendment?), dated as of December 15, 2017, is entered into among CVS Health Corporation, a Delaware corporation (the ?Borrower?), The Bank of New York Mellon, as Administrative Agent and the Lenders party hereto (the ?Consenting Lenders?). Except as otherwise provided herein, capitalized terms used herein which are no
December 19, 2017	EX-2.1	Joinder to Bridge Facility Commitment Letter, dated as of December 15, 2017, by and among Barclays Bank PLC, Goldman Sachs Bank USA, Goldman Sachs Lending Partners LLC, Bank of America, N.A., Merrill Lynch, Pierce, Fenner & Smith Incorporated, CVS Health and each of the Additional Commitment Parties party thereto. EX-2.1 2 d508259dex21.htm EX-2.1 Exhibit 2.1 PERSONAL AND CONFIDENTIAL December 15, 2017 Barclays 745 Seventh Avenue New York, New York 10019 Goldman Sachs Bank USA Goldman Sachs Lending Partners LLC 200 West Street New York, New York 10282-2198 Merrill Lynch, Pierce, Fenner & Smith Incorporated Bank of America, N.A. One Bryant Park New York, New York 10036 CVS Health Corporation One CVS Drive Woo
December 18, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following is a transcript from a video made available to Aetna employees: Mark Bertolini - Holiday Message: Hello, everyone. 2017 was truly an historic year for our company. We continu
December 18, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 15, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) 425 1 dp84204425-56.htm FORM 425 Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following is a transcript from an Aetna town hall: CHS Gary Loveman Town Hall 2017-12-07 [ 00:00:00 ] [Music; scene set up] [ 00:12:55 ] gary loveman G
December 15, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 14, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) 425 1 dp84160425-55.htm FORM 425 Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) Q&A on proposed transaction with CVS Health Contents Announcement 1 Employees 1 Agreement, approvals and closing 2 Integration 3 Customers and other extern
December 14, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 13, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 12, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 12, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 12, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following communication was distributed by Aetna: CVS Health to Acquire Aetna Combination to Provide Consumers with a Better Experience, Reduced Costs and Improved Access to Health Car
December 12, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) 425 1 dp84086425-53.htm FORM 425 Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following talking points are an excerpt of a communication that may be distributed by Aetna in connection with employee recruiting: · We remain committ
December 11, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) Supplemental Q&A for Customers, Brokers, Providers General Q. Will there be any immediate impact to the member medical or pharmacy benefits, provider policies, payment guidelines, service?
December 11, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 11, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following communication may be made available by Aetna on LinkedIn: ?The ramifications of such deals for traditional care providers typically dominated by hospitals is going to be big
December 11, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) Plan Sponsor Employee Message Dear Colleagues, It was recently announced that CVS Health has agreed to acquire Aetna. Aetna?s industry leading health care benefits and services combined wi
December 8, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 8, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 1 d491817d425.htm 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc. Commission File No.: 001-16095 Date: December 7, 2017 The following is a transcript of a video recorded at a Town Hall meeting held on December 5, 2017, which video was subseque
December 7, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 7, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 7, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) 425 1 dp83956425-48.htm FORM 425 Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) Email to Brokers December 3, 2017 To Our Valued Brokers, As you may have heard, CVS Health, the largest pharmacy health care provider in the U.S., has agre
December 7, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following email was distributed by Aetna: Dear , By now, you have likely seen the attached press release announcing that CVS Health has agreed to acquire Aetna. At bswift, we are very
December 6, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) CVS Health + Aetna Revolutionizing the Consumer Health Care Experience December 2017 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 6, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) Aetna made the following communication to brokers: To our valued partners: As you may have seen in the news, CVS Health, the largest pharmacy health care provider in the U.S., has agreed t
December 6, 2017	EX-2.1	Agreement and Plan of Merger among CVS Health Corporation, Hudson Merger Sub Corp. and Aetna Inc. dated as of December 3, 2017, incorporated herein by reference to Exhibit 2.1 to Aetna Inc.’s Form 8-K filed on December 6, 2017. EX-2.1 2 dp83737ex0201.htm EXHIBIT 2.1 Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of December 3, 2017 among CVS HEALTH CORPORATION, HUDSON MERGER SUB CORP. and AETNA INC. TABLE OF CONTENTS Page Article I Definitions Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 16 Article II Closing; THE Merger Section 2.01. Closing
December 6, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2017 (December 3, 2017) Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of incorporation) (C
December 6, 2017	425	AET / Aetna, Inc. FORM 8-K (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2017 (December 3, 2017) Aetna Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-16095 23-2229683 (State or other jurisdiction of incorporation) (C
December 6, 2017	EX-2.1	Agreement and Plan of Merger, dated as of December 3, 2017, among CVS Health Corporation, Hudson Merger Sub Corp. and Aetna Inc.* Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of December 3, 2017 among CVS HEALTH CORPORATION, HUDSON MERGER SUB CORP. and AETNA INC. TABLE OF CONTENTS Page Article I Definitions Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 16 Article II Closing; THE Merger Section 2.01. Closing 17 Section 2.02. The Merger 17 Section
December 6, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 6, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 5, 2017	425	CVS / CVS Health Corporation FORM 8-K (Prospectus) 425 1 d444237d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2017 (December 3, 2017) CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction o
December 5, 2017	EX-2.1	Agreement and Plan of Merger, dated as of December 3, 2017, among CVS Health, Hudson Merger Sub Corp. and Aetna* EX-2.1 Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of December 3, 2017 among CVS HEALTH CORPORATION, HUDSON MERGER SUB CORP. and AETNA INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 16 ARTICLE II CLOSING; THE MERGER Section 2.01. Closing 17 Section 2.02. The Merger 17
December 5, 2017	EX-2.2	Bridge Facility Commitment Letter, dated December 3, 2017, among Barclays Bank PLC, Goldman Sachs Bank USA, Goldman Sachs Lending Partners LLC, Bank of America, N.A., Merrill Lynch, Pierce Fenner & Smith Incorporated and CVS Health. EX-2.2 3 d444237dex22.htm EX-2.2 Exhibit 2.2 EXECUTION VERSION BARCLAYS 745 Seventh Avenue New York, New York 10019 GOLDMAN SACHS BANK USA GOLDMAN SACHS LENDING PARTNERS LLC 200 West Street New York, New York 10282-2198 MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED BANK OF AMERICA, N.A. One Bryant Park New York, New York 10036 PERSONAL AND CONFIDENTIAL December 3, 2017 CVS Health Corporation
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 5, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following communication was circulated via Aetna’s internal website: Dear Colleagues, As you have heard from Mark Bertolini and Gary Loveman, CVS Health has agreed to acquire Aetna. Ou
December 5, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following communications have been made available by Aetna on Twitter: Tweet 1: Together with CVS Health, we will better understand our members’ health goals, guide them through the he
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Company Town Hall December 5, 2017 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 5, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following is a transcript from an Aetna/CVS town hall: CVS-Aetna Town Hall Part 1 [ 00:00:03 ] mark bertolini Good afternoon. [ 00:00:07 ] various speakers Good afternoon. [ 00:00:07 ]
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) Shareholders Expected to Benefit from a Number of Outcomes Benefits for Shareholders Enhanced competitive positioning Low- to mid-single digit accretion in the second full year after close of the transaction * Ability to deliver $750 million in near-term synergies A platform from which to accelerate growth Over the longer-term, potential to deliver significant incremental value through development of new products as a uniquely integrated retailer, pharmacy benefits manager and health plan FINANCIAL SUPPLEMENT Accretion is calculated as a percent of Adjusted EPS based upon First Call consensus figures immediately prior to the announcement of the transaction.
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc.
December 5, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) ?2017 Aetna Inc. Aetna Town Hall Meeting December 4, 2017 ?2017 Aetna Inc. Aetna Town Hall Meeting December 4, 2017 ?2017 Aetna Inc. Important Information for Investors and Shareholders 2
December 5, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) AetNet Article Title: CVS Health agrees to acquire Aetna Today, CVS Health and Aetna announced that they have entered into an agreement under which CVS Health will acquire Aetna. Aetna?s i
December 5, 2017	425	AET / Aetna, Inc. FORM 425 (Prospectus) Filed by Aetna Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aetna Inc. (Commission File No.: 001-16095) The following articles written by third parties were made available via links provided in the above communication: Why the CVS-Aetna Merger Could Benefit Consumers BY Austin Frakt The New
December 5, 2017	425	CVS / CVS Health Corporation 425 (Prospectus) 425 1 d491560d425.htm 425 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aetna Inc. Commission File No.: 001-16095 Date: December 4, 2017 The following was sent to investors and analysts: CVS Health to Acquire Aetna; Combination to Provide Consumers with a Bett

AET / Aetna, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)